World ADC 2024 https://web.hansonwadegroup.com/rs/355-DOS-429/images/World_ADC_San_Diego_2024_Speaker_Interview_Theratechnologies.pdf?utm_source=digital&utm_medium=social-post&utm_campaign=content&utm_content=linkedin/speaker-interview-hw-post/ev-41002
As per potentials for PDCs he mentioned dual payloads attached to peptides and radioligands having less bystander effects(less damage to healthy cells).
Also..
"We are still working to optimize the dose, but the trial program has provided us with some very important information about the unique MOA, the efficacy and improved safety profile, which is very different from that of its payload and from other ADCs already approved for use. This may enable combinations with other anti-cancer agents, such as targeted agents, CPls, and other PDCs/ADCs."